Psychedelic News and Analysis Made Simple for Investors
Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.
Track the entire psychedelic market
We’ve developed the first all encompassing index to track the public psychedelic marketplace.
Explore the Index
Just Some of the Data we Cover
Latest News
Press
Sep 21
•
2 min read
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that its 2023 Annual and Special Meeting of Shareholders will be held virtually on Thursday, October 12, 2023 at 1:00 p.m. ET. The notice of annual and special…
Press
Company also announces that the IMPACT-1 clinical trial is underway with open-label results expected in the coming months Transcend Therapeutics, a biotechnology company developing rapid-acting treatments for neuropsychiatric diseases, announced receipt of a collaborative grant award with Yale University to support first-of-its-kind preclinical research on methylone – Transcend’s lead compound for the treatment of post-traumatic stress disorder…
Sep 21
•
2 min read
Press
Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that based on positive SPC-15 pre-clinical data, it is working with Kymanox as its regulatory partner to assist with…
Sep 21
•
3 min read
Press
–Phase 2 topline efficacy data for CYB003 on track for Q4 2023, followed by U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2 data for pivotal studies – – Breakthrough Therapy designation anticipated in late 2023, subject to FDA approval – – Previously announced acquisition of Small Pharma Inc. expected to close in…
Sep 21
•
4 min read
Press
The import to Filament’s Metro Vancouver facility was conducted in collaboration with the Peruvian government and facilitated by Filament Health and Jaguar Health Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or “Filament Health”), a clinical-stage natural psychedelic drug development company, today announced that Magdalena Biosciences (“Magdalena”), a joint venture formed by Filament and Jaguar Health, Inc. (Nasdaq: JAGX) (“Jaguar…
Sep 21
•
4 min read
Blog
This has been a busy quarter for the psychedelic industry, particularly Lucy Scientific Discovery Inc. The company has announced three acquisitions in the past three months. These acquisitions create an interesting and unexpected pathway for the company. The NASDAQ-listed Lucy Scientific Discovery has greatly expanded its reach within the psychedelic, wellness, and cannabis industries this…
Sep 20
•
6 min read
Blog
Psychedelic Invest’s Charley Rose sat down with the CEO of Red Light Holland, Todd Shapiro. During the interview, Charley does a deep dive into the company and its current positioning in the market. Red Light Holland is an expansive collection of mushroom brands. Todd Shapiro offers a fun and unique perspective on the global psychedelic…
Sep 20
•
1 min read
Explore the Psychedelic Landscape
Learn more about the psychedelic companies changing the industry.